Clinical trials
Hepatitis C Virus (HCV) clinical trials
Below are recruiting hepatitis c virus (hcv) clinical trials, each written for real people, not researchers. We’re tracking 24 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07317687Recruiting
Rapid HIV, Hep C, and Syphilis Testing in Street Medicine
This trial offers free rapid testing for HIV, hepatitis C, and syphilis during street medicine visits. It helps find infections early so you can get connected to care.
Harpers Ferry, West VirginiaAges 18 years+ - NCT03200379Recruiting
Taiwan registry for people treated for hepatitis C
This registry is for people in Taiwan who have received direct-acting antiviral (DAA) treatment for hepatitis C. It collects health information to better understand outcomes and care, and you can join if you agree to participate and sign consent.
Kaohsiung CityAges Any age - NCT05968573Recruiting
Health messages intervention for people at risk of HIV or HCV
This study tests whether persuasive, health-message coaching can help people reduce risk for HIV or hepatitis C (HCV). You may be eligible if you’re not infected with HIV or HCV and haven’t been tested for either in the last year.
New York, New YorkAges 18 years+ - NCT06155006Recruiting
Hepatitis C screening and treatment link in Colombian hospitals
This study offers free hepatitis C testing to adults in Colombian hospitals, especially those with risk factors like past medical or dental procedures, tattoos, drug use, or certain health conditions. If you test positive, the team will help connect you to treatment.
Medellín, AntioquiaAges 18–100 - NCT06431945Recruiting
Hepatitis C testing for injection drug users
This trial offers free hepatitis C testing for people who inject or have injected drugs. The goal is to find hidden cases early so they can get treatment.
BrnoAges 18 years+ - NCT06745895Recruiting
Colorectal cancer and hepatitis C education and screening study
This study helps people who go to certain clinics get screened for colorectal cancer and hepatitis C. It provides information and support to those who haven't had all their recommended screenings yet.
Tampa, FloridaAges 45–75 - NCT06870019Recruiting
Hepatitis C tracker study for unsheltered homelessness
This study tests a simple treatment for Hepatitis C in people experiencing unsheltered homelessness. It aims to help those who are receiving street medicine care and have not been treated before.
Alhambra, CaliforniaAges 18 years+ - NCT07095192Recruiting
Hepatitis C testing and treatment study in Canada
This study looks at how to make hepatitis C testing and treatment easier to access in Canada. It involves different people, like those at risk, healthcare workers, and policy makers, to find better ways to offer care.
Montreal, QuebecAges 18 years+ - NCT07122219Recruiting
Needle exchange access in federal prisons
This study looks at whether making needle and syringe programs easier to use helps more people in prison get clean needles. It's about reducing infection risks for everyone at the participating prisons.
Edmonton, AlbertaAges 18 years+ - NCT07419347Recruiting
Glecaprevir/Pibrentasvir safety in real-world use
This study watches how safe and well-tolerated the 8-week treatment with glecaprevir/pibrentasvir is for people with hepatitis C who are taking other prescription or illicit drugs. It helps doctors learn more about using this medicine in everyday life.
Vancouver, British ColumbiaAges 18 years+ - NCT07433985Recruiting
California mobile app study for men after jail release
This study tests a mobile app to help men recently released from jail or prison who use drugs or have sex with men stay healthy and avoid HIV. It's for people who don't have HIV and live in certain California counties.
Oakland, CaliforniaAges 18–59 - NCT05248919Enrolling by invitation
Study treatment for hepatitis C that did not work before
This trial looks at hepatitis C treatment for people whose last antiviral medicines did not fully clear the virus. It may help by testing a study drug approach for people in Pakistan who still have active hepatitis C infection.
Karachi, SindhAges 18–100 - NCT07024641RecruitingPhase 1
Safety study of GIGA-2339 for chronic Hepatitis B
This study tests an experimental antibody (GIGA-2339) given as an infusion to people with chronic Hepatitis B. It aims to see if the drug is safe and how the body processes it, possibly helping to control the virus.
Chandler, ArizonaAges 18 years+ - NCT06718530Recruiting
Finding early markers for liver cancer in people with chronic liver disease
This study looks for substances in your blood and immune system that could help doctors find liver cancer earlier. It is for people with liver cancer caused by chronic liver problems like hepatitis C, cirrhosis, or scarring.
Aviano, PordenoneAges 18 years+ - NCT06617000RecruitingPhase 1
Immune cell therapy for hepatitis B-related liver cancer
This study tests a new immune cell therapy (SCG101) for people with a certain type of liver cancer linked to hepatitis B. It's designed for those whose cancer has progressed after standard treatments.
Beijing, Beijing MunicipalityAges 18–70 - NCT06367465Recruiting
Hepatitis C treatment during pregnancy
This study tests whether treating hepatitis C during pregnancy is feasible and acceptable for pregnant women who have a history of drug use. If you qualify, you may receive treatment that could help protect your health and your baby's health.
St Louis, MissouriAges 18 years+ - NCT07389044RecruitingPhase 1
Safety study of IB-001 injection in healthy people and hepatitis B patients
This study tests a new injection called IB-001 in two groups: healthy people and people with chronic hepatitis B. The goal is to see if it's safe and how the body handles it at different doses. It might offer a new treatment option for hepatitis B in the future.
ChisinauAges 18–70 - NCT05769816RecruitingPhase 2
Combination treatment aimed to cure chronic hepatitis B
This Phase 2 study tests a combination therapy to help people with chronic hepatitis B reach a “functional cure,” meaning the hepatitis B surface antigen (HBsAg) is lost for a sustained period. If you qualify, you’ll be closely monitored to see how well the treatment works and whether it’s safe for you.
Chongqing, Chongqing MunicipalityAges 18–70 - NCT05771402RecruitingPhase 2
Combination treatment aimed at clearing hepatitis B long-term
This Phase 2 study tests a combination treatment to help people with chronic hepatitis B stop having detectable hepatitis B surface antigen (called HBsAg). If successful, it may move you closer to a “functional cure,” meaning lower ongoing virus activity over time.
Chongqing, Chongqing MunicipalityAges 18–70 - NCT06306300RecruitingPhase 4
Hepatitis C treatment at local clinics vs standard care
This study compares two ways to treat hepatitis C: getting treatment at a local clinic near you, or the usual care at a central hospital. It aims to see if treatment at local clinics is safe, effective, and more convenient for patients.
Rio de Janeiro, Rio de JaneiroAges 18–79 - NCT05832229RecruitingPhase 2
Studying rosuvastatin to slow liver scarring in cirrhosis
This Phase 2 trial tests whether rosuvastatin (a cholesterol-lowering medicine) can improve how well the liver functions and slow worsening scarring in people with cirrhosis. It also checks for side effects and safety.
La Jolla, CaliforniaAges 18–75 - NCT06874127Recruiting
Predicting liver repair in hepatitis B after treatment
This study looks at whether non-invasive tests can tell if liver damage is reversing in people with hepatitis B who have been on antiviral therapy for at least a year. It aims to help avoid repeated liver biopsies.
BeijingAges 18 years+ - NCT06295328RecruitingPhase 1/Phase 2
Terbinafine for chronic hepatitis B: safety and effect
This study tests whether a fungus-fighting drug, terbinafine, can help treat chronic hepatitis B. It is for people with stable disease who are not on other antivirals or are only on tenofovir.
Amsterdam, North HollandAges 18–60 - NCT06455280RecruitingPhase 1
A study of Siplizumab for autoimmune liver disease patients awaiting transplant
This trial tests a drug called Siplizumab in people with autoimmune hepatitis or primary sclerosing cholangitis who are on the liver transplant waitlist. It aims to see if the drug can help manage their condition before and after transplant.
New York, New YorkAges 18 years+
Hear when a new Hepatitis C Virus (HCV) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for hepatitis c virus (hcv)?
- Yes. Clin2 currently lists 24 recruiting hepatitis c virus (hcv) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a hepatitis c virus (hcv) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a hepatitis c virus (hcv) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.